drugset / Trial / NCT00818519

GA YAZ ACNE in China Phase III

NCT00818519

Phase 3 Completed 179 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) in comparison with placebo in female patients with moderate acne vulgaris over 6 treatment cycles.

Timeline

Start
2008-12
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 20 ug Oral

Indications